Fibrous solitary tumor, a rare and ubiquitous neoplasy.

Fibrous solitary tumors (FST) are mesenchymal tumors that can appear in different body regions. It is estimated that around 30% are found in the thoracic region, while rarely in meninges, abdomen, pelvis, extremities and bones. A correct diagnosis is important because 15-20% of cases develop a malignant behavior. Treatment of choice is surgical and posterior follow-up is essential. We present two atypical extrapleural FST cases, diagnosed in our center. Both were treated with surgery and in one case arterial embolization to reduce the bleeding risk was previously done.

Papel de la resección quirúrgica en las metástasis hepáticas de carcinoma de mama: experiencia en los últimos 10 años en un hospital de referencia / Role of resection surgery in breast cancer liver metastases. Experience over the last 10 years in a reference hospital

Introducción: Las metástasis hepáticas de carcinoma de mama (MHCM) se consideran una enfermedad sistémica cuyo tratamiento principal está basado en la quimioterapia, mientras que el papel de la resección quirúrgica sigue sin estar bien definido. El objetivo de este estudio fue analizar la supervivencia y los factores pronósticos predictivos de mortalidad en las pacientes con MHCM tratadas con resección hepática. Material y métodos: Entre 1998–2008 intervinimos a 21 pacientes, realizando resección hepática en 12. Recogimos distintas variables retrospectivamente. Resultados: La edad media fue de 48 años. El estadio más frecuente del tumor primario fue el i , con cirugía curativa en todos los casos, y recibió tratamiento adyuvante la mayoría (66,7%). Las MHCM fueron fundamentalmente metacrónicas (83,3%). Recibió tratamiento neoadyuvante el 66,7%. La resección hepática fue R0 en todos los casos con una morbilidad nula y una mortalidad a largo plazo del 8,3%. Recibió quimioterapia adyuvante el 66,7%. La supervivencia estimada fue del 67% al año y del 23% a los 5 años. Un periodo libre de enfermedad entre el tumor primario y la aparición de metástasis menor de 24 meses se asoció a peor supervivencia. Conclusiones: La resección de las MHCM dentro del manejo multimodal es un tratamiento seguro en pacientes seleccionadas (AU)

Introduction: Breast cancer liver metastases (BCLM) are considered as a systemic disease which is mainly treated with chemotherapy, while the role of surgical resection still remains to be well defined. The aim of the study is to analyse the survival and prognostic factors predictive of mortality in patients with BCLM treated by liver resection. Material and methods: A total of 21 patients were operated on between 1998–2008, with liver resection being performed on 12. We retrospectively collected several variables. Results: The mean age was 48 years. The most frequent stage was I, with curative surgery in all cases, and the majority (66.7%) received adjuvant treatment. The BCLM were mainly meta metachronic (83.3%). The majority (66.7%) received neoadjuvant treatment. The liver resection was R0 in all cases with no morbidity and a mortality in the long term of 8.3%. Two-thirds received chemotherapy. The estimated survival at one year was 67% and 23% at 5 years. A disease free period of less than 24 months between the primary tumour and the appearance of metastasis was associated with a worse survival. Conclusions: Resection of BCLM within a multimodal treatment is safe in selected patients (AU)

[Role of resection surgery in breast cancer liver metastases. Experience over the last 10 years in a reference hospital]. / Papel de la resección quirúrgica en las metástasis hepáticas de carcinoma de mama: experiencia en los últimos 10 años en un hospital de referencia.

INTRODUCTION: Breast cancer liver metastases (BCLM) are considered as a systemic disease which is mainly treated with chemotherapy, while the role of surgical resection still remains to be well defined. The aim of the study is to analyse the survival and prognostic factors predictive of mortality in patients with BCLM treated by liver resection. MATERIAL AND METHODS: A total of 21 patients were operated on between 1998-2008, with liver resection being performed on 12. We retrospectively collected several variables. RESULTS: The mean age was 48 years. The most frequent stage was I, with curative surgery in all cases, and the majority (66.7%) received adjuvant treatment. The BCLM were mainly meta metachronic (83.3%). The majority (66.7%) received neoadjuvant treatment. The liver resection was R0 in all cases with no morbidity and a mortality in the long term of 8.3%. Two-thirds received chemotherapy. The estimated survival at one year was 67% and 23% at 5 years. A disease free period of less than 24 months between the primary tumour and the appearance of metastasis was associated with a worse survival. CONCLUSIONS: Resection of BCLM within a multimodal treatment is safe in selected patients.